MGMA and Jackson Physician Search Extend Partnership to Enhance Physician Recruitment and Retention for Medical Practices

March 27, 2024 UCBN News, Syndication Comments Off on MGMA and Jackson Physician Search Extend Partnership to Enhance Physician Recruitment and Retention for Medical Practices

ENGLEWOOD, Colo. and ATLANTA , March 27, 2024 /PRNewswire/ — The Medical Group Management Association (MGMA) today announced an extended executive partnership with Jackson Physician Search, a national leader in the permanent recruitment of physicians, physician executives and advanced…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Related Articles

No Picture
News

Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

July 12, 2023 UCBN News, Syndication Comments Off on Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

BOULDER, Colo.–(BUSINESS WIRE)—- $BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the […]

No Picture
News

Foresight Diagnostics and Leading Global Cancer Center to Present New Data on Foresight CLARITY™ Ultra-Sensitive MRD Detection in Early-Stage Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

November 25, 2024 UCBN News, Syndication Comments Off on Foresight Diagnostics and Leading Global Cancer Center to Present New Data on Foresight CLARITY™ Ultra-Sensitive MRD Detection in Early-Stage Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

BOULDER, Colo.–(BUSINESS WIRE)–Foresight Diagnostics (Foresight) today announced new data from its ultra-sensitive Foresight CLARITY™ minimal residual disease (MRD) platform in early-stage breast cancer that will be presented at the 2024 San Antonio Breast Cancer Symposium […]